JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

Home・Akciju saraksts・MacroGenics Inc

MacroGenics Inc

Slēgts

SektorsVeselības aprūpe

1.84 0.55

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.81

Max

1.87

Galvenie mērījumi
By Trading Economics
Ienākumi	4.8M -36M
Pārdošana	9M 22M
Peļņas marža	-162.992
Darbinieki	341
EBITDA	5.7M -33M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+104.92% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2025. g. 4. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	15M 108M
Iepriekšējā atvēršanas cena	1.29
Iepriekšējā slēgšanas cena	1.84

Ziņu noskaņojums

By Acuity

50%

145 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Neutral Evidence

1.47 / 1.64 Atbalsts un pretestība

MacroGenics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 24. okt. 18:41 UTC

Peļņas

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

2025. g. 24. okt. 18:31 UTC

Peļņas

Correction to Procter & Gamble to Focus on Innovation

2025. g. 24. okt. 16:25 UTC

Galvenie tirgus virzītāji

Obook Shares Rise, Company Secures New Money Transmitter Licenses

2025. g. 24. okt. 21:24 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 24. okt. 21:24 UTC

Tirgus saruna

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

2025. g. 24. okt. 21:07 UTC

Peļņas

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

2025. g. 24. okt. 20:58 UTC

Peļņas

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

2025. g. 24. okt. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 24. okt. 20:40 UTC

Peļņas

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

2025. g. 24. okt. 20:24 UTC

Peļņas

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

2025. g. 24. okt. 20:23 UTC

Peļņas

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

2025. g. 24. okt. 20:13 UTC

Peļņas

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

2025. g. 24. okt. 20:07 UTC

Tirgus saruna

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

2025. g. 24. okt. 19:40 UTC

Tirgus saruna

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

2025. g. 24. okt. 19:35 UTC

Tirgus saruna

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

2025. g. 24. okt. 19:33 UTC

Peļņas

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

2025. g. 24. okt. 19:29 UTC

Tirgus saruna

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

2025. g. 24. okt. 18:52 UTC

Peļņas

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

2025. g. 24. okt. 18:41 UTC

Peļņas

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

2025. g. 24. okt. 18:03 UTC

Peļņas

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

2025. g. 24. okt. 18:02 UTC

Peļņas

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

2025. g. 24. okt. 18:00 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

2025. g. 24. okt. 16:57 UTC

Peļņas

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

2025. g. 24. okt. 16:54 UTC

Tirgus saruna

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

2025. g. 24. okt. 16:44 UTC

Tirgus saruna

Peļņas

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

2025. g. 24. okt. 16:39 UTC

Tirgus saruna

Peļņas

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

2025. g. 24. okt. 16:33 UTC

Peļņas

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

2025. g. 24. okt. 16:23 UTC

Peļņas

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

2025. g. 24. okt. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 24. okt. 16:07 UTC

Peļņas

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

MacroGenics Inc Prognoze

Cenas mērķis

By TipRanks

104.92% augšup

Prognoze 12 mēnešiem

Vidējais 3.75 USD 104.92%

Augstākais 5 USD

Zemākais 3 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi MacroGenics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam MacroGenics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

1.47 / 1.64Atbalsts un pretestība

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

145 / 371 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.